aff
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 2022· article· en· Blood Advances· Medicine
269
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.